AlphAIAlphAI — Financial news for AI agents
massdevice.comOCT 52 min read$GEHC

GE HealthCare to buy Sofie Biosciences in $945M radiopharmaceutical play

GE HealthCare (GEHC) will acquire Sofie Biosciences for $945M to strengthen its radiopharmaceutical supply chain. The deal includes 15 U.S. manufacturing sites and 21 cyclotrons, aiming to support short-half-life imaging agents. Sofie's FAPI-74 radiotracer, in phase 3 trials, targets pancreatic and gastroesophageal tumors. The acquisition is expected to close in early 2025.

Original reporting
massdevice.com
Published Oct 5, 2026, 2:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 3:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
GE HealthCare to buy Sofie Biosciences in $945M radiopharmaceutical play — source image
Source · massdevice.com
Decision brief

The 30-second read

$GEHCBullishHigh
01

Why it matters

The acquisition positions GEHC to capture higher margins in the expanding radiopharma market and may drive share price appreciation.

02

Market read

A major M&A move in the healthcare sector with potential upside for GEHC and broader implications for PET imaging supply chains.

03

What to watch

Regulatory approvals for new radiotracers and integration risks may delay expected benefits.

Relevance 9/10Novelty 9/10Timing: immediate reaction today

Background

GE HealthCare seeks to secure end‑to‑end control of PET radiotracer production amid rapid market growth.

Company-level read

Ticker impact

$GEHCBullishHigh confidence
Context

GE HealthCare announced a $945M cash acquisition of Sofie Biosciences, expanding its radiopharmaceutical supply chain.

Expected impact

upward pressure as the market prices in acquisition synergies and expanded market reach

Evidence & confidence

Large cash deal, strategic fit, and immediate market reaction suggest a positive impact on GEHC's share price.

Market effects

Sector

Strengthens GE HealthCare's position in the radiopharmaceutical and PET imaging sector.

Regional

Impacts the U.S. healthcare and diagnostic imaging market.

Global

Enhances global supply of F‑18 PET tracers, affecting worldwide diagnostic imaging services.

Counterpoint

What could challenge this read

The sizable cash outlay could strain GEHC's balance sheet and dilute earnings per share.

Key entities

  • Company
    GE HealthCare

    U.S. listed medtech company acquiring Sofie Biosciences.

  • Company
    Sofie Biosciences

    Private radiopharmaceutical contract manufacturer.

Read at source← All news

StoryGE HealthCare agrees $945 million purchase of SOFIE Biosciences

Also covered by

6 outlets

Related articles

OCT 7
$GEHCHighAI 9/10

GE HealthCare to acquire SOFIE Biosciences for $945 million, expanding U.S. PET supply footprint

GE HealthCare will acquire SOFIE Biosciences for $945 million in cash, expanding its U.S. PET radiopharmaceutical supply. The deal, expected to close in early 2027, will add SOFIE's 15 manufacturing sites and 21 cyclotrons to GE HealthCare's Pharmaceutical Diagnostics segment, enhancing its theranostics capabilities and access to high-growth areas. SOFIE's FAPI-74 radiopharmaceutical is in Phase III trials.

gmtoday.com2 min
OCT 7
$GEHCHighAI 9/10

GE HealthCare Agreed to Buy Trilantic-Backed SOFIE Biosciences for $945 Million:

GE HealthCare agreed to buy SOFIE Biosciences, a U.S. contract manufacturer of PET radiopharmaceuticals, for $945 million in cash. The deal, expected to close in early 2027, includes SOFIE's 15 U.S. manufacturing sites and rights to FAPI-74, an experimental PET imaging agent. SOFIE will continue serving existing customers post-acquisition. Trilantic North America, SOFIE's private equity backer, sold the company to GE HealthCare, which aims to expand its pharmaceutical diagnostics segment.

hedgeco.net2 min